Psoriasis as autoinflammatory disease

Dermatologic Clinics

Volumn 31, Issue 3, 2013, Pages 445-460

  Rivas Bejarano, Joaquin J ^a,b   Valdecantos, Wendell C ^a  

^a ABBVIE INC   (United States)

^b LONE STAR COLLEGE   (United States)

Author keywords

Autoinflammatory disease; Cytokines; Genetics; Immunopathogenesis; Inflammasome; Psoriasis; TH cells; TNF

Indexed keywords

ANGIOPOIETIN; C REACTIVE PROTEIN; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; ENDOTHELIAL CELL GROWTH FACTOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; PADGEM PROTEIN; THYMIDINE PHOSPHORYLASE; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADAPTIVE IMMUNITY; ANTIGEN SPECIFICITY; AUTOIMMUNITY; AUTOINFLAMMATORY DISEASE; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL MIGRATION; CLINICAL FEATURE; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE COURSE; ENVIRONMENTAL FACTOR; ERYTHRODERMIC PSORIASIS; GENETIC ASSOCIATION; GUTTATE PSORIASIS; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOPHENOTYPING; IMMUNOSTIMULATION; INCIDENCE; INNATE IMMUNITY; INVERSE PSORIASIS; KERATINOCYTE; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC INFILTRATION; PRIORITY JOURNAL; PROTEIN FOLDING; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PUSTULAR PSORIASIS; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL;

AUTOINFLAMMATORY DISEASE; CYTOKINES; GENETICS; IMMUNOPATHOGENESIS; INFLAMMASOME; PSORIASIS; TH CELLS; TNF-Α;

AUTOIMMUNE DISEASES; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; PSORIASIS;

EID: 84879864813     PISSN: 07338635     EISSN: 15580520     Source Type: Journal    
DOI: 10.1016/j.det.2013.04.009     Document Type: Review

References (67)

1. Yao Q., Furst D. Autoinflammatory diseases: an update of clinical and genetic aspects. Rheumatology 2008, 47(7):946-995.
2. Masters S., Simon A., Aksentijevich I., et al. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory diseases. Annu Rev Immunol 2009, 27:621-668. NIH Public Access. Author Manuscript.
3. Houten S.M., Kuis W., Duran M., et al. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nat Genet 1999, 22:175-177.
4. Galon J., Aksentijevich I., McDermott M.F., et al. TNFRSF1A mutations and autoinflammatory syndromes. Curr Opin Immunol 2000, 12:479-486.
5. Amagay M., Kouji M. Overview of autoimmunity and autoinflammation. Inflamm Reagen Jan 2011, 31(1):50-51.
6. Lamprecht P., Gross W.L. Autoinflammatory syndromes. Internist (Berl) 2009, 50(6):676-684. [in German]. 10.1007/s00108-009-2302-5.
7. The NOMID Alliance: The NOMID Alliance is a 501 (c) (3) non-profit public charity dedicated to promoting awareness, proper diagnosis and treatment, and improved care for people with CAPS (Cryopyrin-Associated Periodic Syndromes) and other autoinflammatory diseases. Awareness publication of the NIAMS and NIH. Information clearinghouse. Available at: Accessed March, 2010. http://www.niams.nih.gov.
8. Stankovic K., Grateau G. What's new in autoinflammatory diseases?. Rev Med Interne 2008, 29(12):994-999. [in French].
9. Stefanova I., Dorfman J.R., Germain R.N. Self-recognition promotes the foreign antigen sensitivity of naive T lymphocytes. Nature 2002, 420(6914):429-434.
10. Pike B., Boyd A., Nossal G. Clonal anergy: the universally anergic B lymphocyte. Proc Natl Acad Sci U S A 1982, 79(6):2013-2017.
11. Jerne N. Towards a network theory of the immune system. Ann Immunol (Paris) 1974, 125C(1-2):373-389.
12. Edwards J.C., Cambridge G., Abrahams V.M. Do self-perpetuating B lymphocytes drive human autoimmune disease?. Immunology 1999, 97:1868-1876.
13. Klein J., Sato A. The HLA system. Second of two parts. NEngl J Med 2000, 343(11):782-786.
14. Edwards J.C., Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006, 6(5):394-403. 10.1038/nri1838.
15. Kubach J., Becker C., Schmitt E., et al. Dendritic cells: sentinels of immunity and tolerance. Int J Hematol 2005, 81(3):197-203. 10.1532/IJH97.04165.
16. Srinivasan R., Houghton A.N., Wolchoks J.D. Induction of autoantibodies against tyrosinase-related proteinsfollowing DNA vaccination: unexpected reactivity toa protein paralogue. Cancer Immun 2002, 2:8.
17. Willam R. On cutaneous diseases 1809, Kimber & Conrad, Philadelphia, Early Autoimmune imprints. Second Series No. 19235.
18. Nestle F.O., Kaplan D.H., Barker J. Psoriasis. NEngl J Med 2009, 361(5):496-509.
19. Griffiths C.E., Barker J.N. Pathogenesis and clinical features of psoriasis. Lancet 2007, 370(9583):263-271.
20. Rahman P., Elder J.T. Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005, 64(Suppl 2):ii37-ii39.
21. Langley R.G., Krueger G.G., Griffiths C.E. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005, 64(Suppl 2):ii18-ii23.
22. Menter A., Gottlieb A., Feldman S., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. JAm Acad Dermatol 2008, 58:826-850.
23. Sabat R., Philipp S., Hoflich C., et al. Immunopathogenesis of psoriasis. Exp Dermatol 2007, 16(10):779-798.
24. Naldi L., Chatenoud L., Linder D., et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. JInvest Dermatol 2005, 125(1):61-67.
25. Gunnarsson C., Chen J., Rizzo J.A., et al. The direct healthcare insurer and out-of-pocket expenditures of psoriasis: evidence from a United States national survey. JDermatolog Treat 2012, 23(4):240-254.
26. Nickoloff B.J., Qin J.Z., Nestle F.O. Immunopathogenesis of psoriasis. Clin Rev Allergy Immunol 2007, 33(1-2):45-56.
27. Nickoloff B.J. The cytokine network in psoriasis. Arch Dermatol 1991, 127:871-884.
28. Gottlieb A.B. Psoriasis: emerging therapeutic strategies. Nat Rev Drug Discov 2005, 4:19-34.
29. Krueger J.G. The immunologic basis for the treatment of psoriasis with new biologic agents. JAm Acad Dermatol 2002, 46:1-23.
30. Coimbra S., Figueiredo A., Castro E., et al. The roles of cells and cytokines in the pathogenesis of psoriasis. Int J Dermatol 2012, 51(4):389-395.
31. Lowes M.A., Russell C.B., Martin D.A., et al. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol 2013, 34(4):174-181. pii:S1471-4906(12)00199-8. 10.1016/j.it.2012.11.005.
32. Mudigonda P., Mudigonda T., Feneran A.N., et al. Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis. Dermatol Online J 2012, 18(10):1.
33. Alexandroff A.B., Pauriah M., Lang C.C., et al. Atherosclerosis as a systemic feature of psoriasis. Clin Exp Dermatol 2011, 36(5):451-452.
34. Armstrong A.W., Voyles S.V., Armstrong E.J., et al. Atale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis. Exp Dermatol 2011, 20(7):544-549.
35. Rogler G. Update in inflammatory bowel disease pathogenesis. Curr Opin Gastroenterol 2004, 20:311-317.
36. Arkan M.C., Hevener A.L., Greten F.R., et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 2005, 11:191-198.
37. Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. JEur Acad Dermatol Venereol 2012, 26(Suppl 2):3-11.
38. Himmerich H., Fulda S., Linseisen J., et al. Depression, comorbidities and the TNF-alpha system. Eur Psychiatry 2008, 23(6):421-429.
39. Kambe N., Satoh S., Nakamura Y., et al. Autoinflammatory diseases and the inflammasome: mechanisms of IL-1β activation leading to neutrophil-rich skin disorders. Inflamm Regen 2011, 31(1):72-80.
40. Christophers E. Psoriasis: heterogeneity, innate immunity and comorbidities. Expet Rev Dermatol 2012, 7(2):195-202.
41. Hebra F. On diseases of the skin including the exanthemata 1868, New Sydenham Society, London.
42. Von Zumbusch L. Psoriasis und pustulöses exanthem. Arch Dermatol Syph 1910, 99:335-346.
43. Asumalahti K., Ameen M., Suomela S., et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. JInvest Dermatol 2003, 120(4):627-632.
44. Marrakchi A., Guigue P., Renshaw B.R., et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. NEngl J Med 2011, 365(7):620-628.
45. Onoufradis A., Simpson M.A., Pink A.E., et al. Mutations in IL36RN/IL1F5 are associated with severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet 2011, 89(3):432-437.
46. Bowcock A.M., Krueger J.G. Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol 2005, 5(9):699-711.
47. Jabbari A., Johnson-Huang L.M., Krueger J.G. Role of the immune system and immunological circuits in psoriasis. GItal Dermatol Venereol 2011, 146(1):17-30.
48. Gudjonsson J.E., Ding J., Johnston A., et al. Assessment of the psoriatic transcriptosome in a large sample: additional regulated genes and comparisons with invitro models. JInvest Dermatol 2010, 130(7):1829-1840.
49. Elder J.T., Bruce A.T., Gudjonsson J.E., et al. Molecular dissection of psoriasis: integrating genetics and biology. JInvest Dermatol 2009, 130(5):1213-1226.
50. Prens E. Linking innate and adaptive immunity in psoriasis. Presented at: Psoriasis: From Gene to Clinic. London, December 1-3, 2011.
51. Schön M.P., Ruzicka T. Psoriasis: the plot thickens. Nat Immunol 2001, 2(2):91.
52. Zur Stadt U., Beutel K., Kolberg S., et al. Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses of PRF1, UNC13D, STX11, and RAB27A. Hum Mutat 2006, 27:62-68.
53. Janka G.E. Familial and acquired hemophagocytic lymphohistiocytosis. Eur J Pediatr 2007, 166:95-109.
54. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. NEngl J Med 2005, 352:1685-1695.
55. Branderup F., Holm N., Grunnet N., et al. Psoriasis in monozygotic twins: variations in expression in individuals with identical genetic constitution. Acta Derm Venereol 1982, 62(3):229-236.
56. Henseler T., Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. JAm Acad Dermatol 1985, 13(3):450-456.
57. Salskov-Iversen M.L., Johansen C., Kragballe K., et al. Caspase-5 expression is upregulated in lesional psoriatic skin. JInvest Dermatol 2011, 131(3):670-676.
58. Lande R., Gregorio J., Facchinetti V., et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007, 449(7162):564-569.
59. Dombrowski Y., Peric M., Koglin S., et al. Cytosolic DNA triggers inflammasome activation in keratinocytes in psoriatic lesions. Sci Transl Med 2011, 3(82):82ra38.
60. McGonagle D., Ash Z., Dickie L., et al. The early phase of psoriatic arthritis. Ann Rheum Dis 2011, 70(Suppl 1):71-76.
61. McGonagle D., McDermott M.F. Aproposed classification of the immunologic diseases. PLoS Med 2006, 3:1242-1248.
62. Husted J.A., Thavaneswaran A., Chandran V., et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res 2011, 63(12):1729-1735.
63. Shapiro J., Cohen A.D., David M., et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case control study. JAm Acad Dermatol 2007, 56(4):629-634.
64. Gelfand J.M., Neimann A.L., Shiin D.B., et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006, 296(14):1735-1741.
65. Federman D.G., Shelling M., Prodanovich S., et al. Psoriasis: an opportunity to identify cardiovascular risk. Br J Dermatol 2009, 160(1):1-7.
66. Aronson P.J. A review of the role of neutrophils in psoriasis and related disorders. Dermatol Online J 2008, 14(7):7.
67. Wetzel A., Wetzig T., Haustein U.F., et al. Increased neutrophil adherence in psoriasis: role of the human endothelial cell receptor Thy-1 (CD90). JInvest Dermatol 2006, 126:441-452.